Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle invasive Bladder Cancer: Con

The use of sequential intravesical instillation of gemcitabine and docetaxel in the management of bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer should not be recommended as a second-line treatment. First, technical issues are a barrier to broad adoption of this strategy. Second, the low level of evidence supporting this treatment remains weak and needs proper assessment.